Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: China Clear all

369 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20062
20072
20084
20096
20104
201111
20126
201318
201417
20158
201616
201732
201819
201919
202013
202126
202225
202340
202430
202540
202627

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed159
Unknown status112
Recruiting57
Not yet recruiting17
Active, not recruiting13
Terminated7
Enrolling by invitation3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca24
GlaxoSmithKline17
Zhujiang Hospital17
Guangzhou Institute of Respiratory Disease16
China-Japan Friendship Hospital15
Peking University Third Hospital15
The First Affiliated Hospital of Guangzhou Medical University15
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.14
Boehringer Ingelheim13
Henan University of Traditional Chinese Medicine10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive369
Asthma20
Bronchitis, Chronic14
Respiratory Insufficiency13
Emphysema11
Lung Diseases11
Bronchiectasis10
Bronchitis5
Disease5
Lung Diseases, Interstitial5

Trials

Showing 1 to 25 of 369. Each trial links to its page on Pharma Observatory.

269 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.